Using TouchWorks® Capabilities

BLENREP
belantamab mafodotin-blmf
for injection 70 mg

To Include BLENREP in Treatment Plans, Send Ophthalmic Exam Notifications, and Monitor Patients' Results

BLENREP is available only through a restricted program called the BLENREP REMS because of the risk of ocular toxicity.

Notable requirements of the BLENREP REMS include the following:

Prescribers must be certified in the BLENREP REMS by enrolling and completing training. Prescribers must counsel patients receiving BLENREP on the risk of ocular toxicity, the need for monitoring via ophthalmic exams before each dose, and provide patients with the BLENREP REMS Patient Guide. Patients must be enrolled in the BLENREP REMS and adhere to monitoring. Healthcare settings that dispense BLENREP must be certified in the BLENREP REMS by enrolling and must obtain authorization prior to dispensing. Wholesalers and distributors must distribute BLENREP only to certified healthcare settings.

Further information is available at www.BLENREPREMS.com and 1-855-690-9572.

INDICATION

BLENREP is indicated in combination with bortezomib and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least two prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent.

IMPORTANT SAFETY INFORMATION

WARNING: OCULAR TOXICITY

- **BLENREP causes changes in the corneal epithelium resulting in changes in vision, including severe visual impairment, and symptoms such as blurred vision and dry eyes. In the clinical study, corneal ulcers, including cases with infection, also occurred.**
- **Conduct ophthalmic exams at baseline, before each dose, promptly for new or worsening symptoms, and as clinically indicated. In the clinical study, 83% of patients required a dosage modification due to ocular toxicity. Withhold BLENREP until improvement and resume or permanently discontinue, based on severity.**
- **Because of the risk of ocular toxicity, BLENREP is available only through a restricted program called the BLENREP Risk Evaluation and Mitigation Strategy (REMS).**

Please see additional Important Safety Information throughout and click here for full Prescribing Information including Boxed Warning for BLENREP.

About This Guide

This electronic health record (EHR) guide is intended to help healthcare providers (HCPs) use TouchWorks® capabilities to facilitate accurate prescribing for BLENREP. It includes steps and examples for adding BLENREP to Order Groups, automating notifications for HCPs and patients about REMS requirements, the need for ophthalmic exams and complete blood count (CBC) tests as directed in the USPI, and customizing Flowsheets to capture and monitor patients' overall ophthalmic exam results grading which can be used to inform BLENREP treatment decisions in line with the USPI.

This guide does not constitute guidance for treatment or medical advice. It is the HCP's responsibility to select a treatment based on their independent medical judgment and the needs of each individual patient.

The examples and instructions listed in this guide are based upon the most recent version of TouchWorks. Locations, illustrations, and terminology are subject to change with system updates. This guide is meant to serve as an overview only and should not replace detailed instructions provided to you by your internal or external EHR support resources. GSK makes no claims or warranties about the applicability or appropriateness of this information. This guide has not been reviewed or endorsed by TouchWorks or Altera Digital Health. GSK does not endorse or recommend any EHR system.

Use the links in the table of contents below or the tabs on each page to navigate this guide.

Table of Contents

INDICATION

BLENREP is indicated in combination with bortezomib and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least two prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent.

IMPORTANT SAFETY INFORMATION

WARNING: OCULAR TOXICITY

- **BLENREP causes changes in the corneal epithelium resulting in changes in vision, including severe visual impairment, and symptoms such as blurred vision and dry eyes. In the clinical study, corneal ulcers, including cases with infection, also occurred.**
- **Conduct ophthalmic exams at baseline, before each dose, promptly for new or worsening symptoms, and as clinically indicated. In the clinical study, 83% of patients required a dosage modification due to ocular toxicity. Withhold BLENREP until improvement and resume or permanently discontinue, based on severity.**
- **Because of the risk of ocular toxicity, BLENREP is available only through a restricted program called the BLENREP Risk Evaluation and Mitigation Strategy (REMS).**

Please see additional Important Safety Information throughout and click here for full Prescribing Information including Boxed Warning for BLENREP.

BLENREP
belantamab mafodotin-blmf
for injection 70 mg

Updating an Order Group to Include BLENREP

When new information or data become available, oncology practices may update or create Order Groups that include administration instructions as well as necessary tests such as ophthalmic exams and REMS requirements (i.e., completed and submitted Patient Status Form before each dose of BLENREP and obtaining authorization to dispense for all doses). Order Groups help care teams facilitate care by grouping together clinical actions that will be administered to a patient during multiple encounters over a specific time frame.

Prescribers must be certified in the BLENREP REMS by enrolling and completing training at www.BLENREPREMS.com. Healthcare settings that dispense BLENREP must be certified in the BLENREP REMS by enrolling at www.BLENREPREMS.com and must obtain authorization prior to dispensing BLENREP. If the practice has an existing Order Group for multiple myeloma and is certified in the BLENREP REMS, BLENREP can be added as a treatment option.

Updating existing Order Groups or adding new Order Groups is typically managed by the practice information technology (IT) EHR specialist or upon request by TouchWorks®. Using an established process for requesting, approving, and implementing a new Order Group may help with predictable management of the EHR.

NOTE: *The specific Order Group components listed below are for illustrative purposes only.*

Steps for Updating an Existing Order Group

1. Navigate to **Orders**.
2. Right-click in the **Orders** section to display the context menu. Choose **Organize Favorites**.
3. From the list of existing Order Groups and Favorited items, select **BLENREP**.
4. Choose **Copy Item...**.
5. Select the **Multiple Myeloma Order Group** folder and appropriate subfolder to be modified.
6. Select **Done**.



Illustrative example of Organize Favorites (recreated from TouchWorks)

IMPORTANT SAFETY INFORMATION (cont.)

WARNINGS AND PRECAUTIONS

Ocular Toxicity

BLENREP causes ocular toxicity, defined as changes in the corneal epithelium and changes in BCVA based on ophthalmic exam (including slit lamp exam), or other ocular adverse reactions as defined by the CTCAE.

In DREAMM-7, ocular toxicity occurred in 92% of patients, including Grade 3 or 4 in 77% of patients. The most common ocular toxicities (>25%) were reduction in BCVA (89%) and corneal exam findings (86%) based on ophthalmic exam findings, blurred vision (66%), dry eye (51%), photophobia (47%), foreign body sensation in eyes (44%), eye irritation (43%), and eye pain (33%).

Please see additional Important Safety Information throughout and click here for full Prescribing Information including Boxed Warning for BLENREP.

BLENREP
belantamab mafodotin-blmf
for injection 70 mg

Updating an Order Group to Include BLENREP (cont.)

Steps for Updating an Existing Order Group (cont.)

7. Repeat this process to add other orders associated with BLENREP, including:
    a. Before treatment
        i. Prescriber REMS certification
        ii. Patient REMS enrollment and counseling
        iii. Patient Status Form submitted before each dose of BLENREP
        iv. REMS authorization to administer before each dose of BLENREP
        v. Ophthalmic exam (including slit lamp and visual acuity)
        vi. Complete Blood Count (CBC)
        vii. Pregnancy testing for females of reproductive potential
        viii. Patient weight
    b. During treatment
        i. Complete Blood Count (CBC)
        ii. Ophthalmic exam (including slit lamp and visual acuity)
        iii. Patient weight

NOTE: *Items added to Order Groups must be set up as Orderable Items and added to the user's Favorites before starting these steps.*

IMPORTANT SAFETY INFORMATION (cont.)

WARNINGS AND PRECAUTIONS (cont.)

Ocular Toxicity (cont.)

Ocular toxicity based on ophthalmic exam findings was reported as Grade 2 in 9% of patients, Grade 3 in 56% of patients, and Grade 4 in 21% of patients. The median time to onset of the first Grade 2 to 4 ophthalmic exam findings was 43 days (range: 15 to 611 days). The median duration of all Grade 2 to 4 ophthalmic exam findings was 85 days (range: 5 to 813 days). Patients experienced a median of 3 episodes (range: 1 to 11 episodes) of ocular toxicity based on ophthalmic exam findings. Of the patients with Grade 2 to 4 ophthalmic exam findings, 42% had improvement of the last event to Grade 1 or better; 22% had resolution of the last event based on return to baseline or normal ophthalmic exam findings.

Please see additional Important Safety Information throughout and click here for full Prescribing Information including Boxed Warning for BLENREP.

BLENREP
belantamab mafodotin-blmf
for injection 70 mg

Creating an Order Group to Include BLENREP

Order Groups help care teams facilitate care by grouping together clinical actions that will be administered to a patient during multiple encounters over a specific time frame.

The following steps provide an overview of the process for creating a new multiple myeloma Order Group to include BLENREP.

Steps for Creating a New Order Group

1. Set up all items as **Orderable Items** and add each order associated with BLENREP, including:
   a. Before treatment
      i. Prescriber REMS certification
      ii. Patient REMS enrollment and counseling
      iii. Patient Status Form submitted before each dose of BLENREP
      iv. REMS authorization to administer before each dose of BLENREP
      v. Ophthalmic exam (including slit lamp and visual acuity)
      vi. Complete Blood Count (CBC)
      vii. Pregnancy testing for females of reproductive potential
      viii. Patient weight
   b. During treatment
      i. Complete Blood Count (CBC)
      ii. Ophthalmic exam (including slit lamp and visual acuity)
      iii. Patient weight



Illustrative example of My Favorites (recreated from TouchWorks)

2. Navigate to **Orders**.
3. Right-click in the **Orders** section to display the context menu. Choose **Organize Favorites – My Favorites**.

IMPORTANT SAFETY INFORMATION (cont.)

WARNINGS AND PRECAUTIONS (cont.)

Ocular Toxicity (cont.)

The most commonly reported corneal exam findings included superficial punctate keratopathy, microcyst-like deposits, epithelial changes, and haze. Cases of corneal ulcer, including cases with infection, have been reported and should be managed promptly by an eye care professional.

A reduction in BCVA to 20/50 or worse in at least one eye occurred in 69% of patients, including 29% who experienced a change in BCVA to 20/100 or worse, and 12% who experienced a change in BCVA to 20/200 or worse. Of the patients with reduced BCVA to 20/50 or worse in at least one eye, 61% had resolution of the last event to baseline or better. Of the patients with reduced BCVA to 20/100 or worse, 57% had resolution of the last event. Of the patients with reduced BCVA to 20/200 or worse, 48% had resolution of the last event.

Please see additional Important Safety Information throughout and click here for full Prescribing Information including Boxed Warning for BLENREP.

BLENREP
belantamab mafodotin-blmf
for injection 70 mg

Creating an Order Group to Include BLENREP (cont.)

Steps for Creating a New Order Group (cont.)

4. Select **New Order Group** and name the new group folder appropriately.
5. Highlight the new folder and create additional Order Group subfolders for the treatment types such as Pre-treatment, Biologics, Additional Medications, and Referrals.
6. From the list of Favorite items, select the **BLENREP** item to be copied.
7. Choose **Copy Item...** then select the appropriate folder.
8. Repeat for each item to be included in the Order Group.

NOTE: *A favorite item can be copied to multiple folders when applicable in various treatment cycles and days.*



Illustrative example of creating new subfolders (recreated from TouchWorks)

Include the BLENREP REMS Eye Care Professional Exam Form available at **www.BLENREPREMS.com** as part of the BLENREP Order Group. The form should be completed by the patient's optometrist or ophthalmologist and sent (via eFax, Fax, EMR, or by the patient) to the oncologist at the close of the patient's eye exam to give the oncologist time to determine appropriate treatment dosing prior to administration of BLENREP. If supported, work with your EHR IT team to add the form as an orderable Item.

IMPORTANT SAFETY INFORMATION (cont.)

WARNINGS AND PRECAUTIONS (cont.)

Ocular Toxicity (cont.)

Ophthalmic exams (including slit lamp exam and BCVA assessment) should be conducted by an eye care professional, such as an ophthalmologist or optometrist, at baseline, before each dose of BLENREP, promptly for new or worsening symptoms, and as clinically indicated. Perform baseline exam within 4 weeks prior to the first dose. Perform each follow-up exam within 10 days prior to the next planned dose. All effort should be made to schedule the exam as close to BLENREP dosing as possible. Withhold BLENREP until improvement in both corneal exam findings and change in BCVA to Grade 1 or less and resume at same or reduced dose or permanently discontinue based on severity.

Please see additional Important Safety Information throughout and click here for full Prescribing Information including Boxed Warning for BLENREP.

BLENREP
belantamab mafodotin-blmf
for injection 70 mg

Creating Automated Patient Reminders

This workflow allows HCPs to draft and set up Patient Reminders that are delivered to the patient via the patient portal. By adding Patient Reminders to a BLENREP Order Group, patients who are prescribed BLENREP will automatically receive a patient portal message with a reminder to complete requirements prior to administration of BLENREP, including patient enrollment in the BLENREP REMS to document that they were counseled and agree to adhere to ophthalmic monitoring, required ophthalmic exams, completed BLENREP REMS Eye Care Professional Exam Form, etc.

Steps for Creating Reminders for Patients Prescribed BLENREP

1. Navigate to **Site Map** > **TW Administration** > **Patient Query**.
2. Click the **Manage Queries** button to create a new query.
3. Enter the title of the new **Query Name**, then click the green plus sign icon ⊕ to open the **Clinical Rules Editor**.



Illustrative example of Query success confirmation (recreated from TouchWorks)

4. Select patient query criteria by clicking on the **Criteria** links from the list on the left side of the screen.
5. Select the **Filter Options**:
   a. **Appointment**
   b. Search for and select **Appt Type**
   c. Select **Appointment Status**
   d. Select **Appointment Occurred**
6. Click **Save and Return**.
7. Close the window and navigate back to **Clinical Rules Editor**.

IMPORTANT SAFETY INFORMATION (cont.)

WARNINGS AND PRECAUTIONS (cont.)

Ocular Toxicity (cont.)

Counsel patients to promptly inform their healthcare provider of any ocular symptoms. Counsel patients to use preservative-free artificial tears at least 4 times a day starting with the first infusion and continuing until the end of treatment, and to avoid wearing contact lenses for the duration of therapy. Bandage contact lenses may be used under the direction of an eye care professional.

Please see additional Important Safety Information throughout and click here for full Prescribing Information including Boxed Warning for BLENREP.

BLENREP
belantamab mafodotin-blmf
for injection 70 mg

Creating Automated Patient Reminders (cont.)

Steps for Creating Reminders for Patients Prescribed BLENREP (cont.)

8. Click the **Refresh All** icon to review the newly created query.
9. Navigate back to TouchWorks® and **Site Map** > **Patient Query**.
10. Search for and highlight the query.
11. Click **New**.
12. In **Add/Edit Patient Action Set**, select **Patient Communication** tab.
13. Create a new action set by selecting **Patient Communication via Portal**.



Illustrative example of new Action Set creation (recreated from TouchWorks)

14. Navigate to **Patient Query** and select **Manage Query**.
15. Search for and highlight the query.
16. Click the **Run** icon.
17. Validate that the query has run successfully.
18. Patient communication is automatically triggered after the query runs.

IMPORTANT SAFETY INFORMATION (cont.)

WARNINGS AND PRECAUTIONS (cont.)

Ocular Toxicity (cont.)

Changes in visual acuity may be associated with difficulty for driving and reading. Counsel patients to use caution when driving or operating machinery.

Please see additional Important Safety Information throughout and click here for full Prescribing Information including Boxed Warning for BLENREP.

BLENREP
belantamab mafodotin-blmf
for injection 70 mg

Creating Automated HCP Inbox Messages

TouchWorks® allows HCPs to draft and set up silent notifications called Inbox Messages. These Inbox Messages could include a reminder to verify prescriber REMS certification and patient REMS enrollment, complete a BLENREP REMS Eye Care Professional Exam Form, submit a Patient Status Form before each dose of BLENREP, obtain authorization to dispense, or to follow up with patients prior to upcoming infusions to ensure that they have completed their requirements prior to administration of BLENREP, including patient enrollment in the BLENREP REMS to document that they were counseled and agree to adhere to ophthalmic monitoring, required ophthalmic exams, completed BLENREP REMS Eye Care Professional Exam Form, etc. Additionally, an Inbox Message may be used to remind HCPs about ordering labs or checking REMS requirements such as prescriber certification, patient enrollment, dispensing healthcare setting certification, completed and submitted Patient Status Form, authorization code prior to dispensing, etc.

Steps for Creating an Inbox Message

1. Navigate to **Site Map** > **TW Administration** > **Patient Query**.
2. Click the **Manage Queries** button to create a new query.
3. Enter the title of the new **Query Name** and then click the green plus sign icon to open the **Clinical Rules Editor**.
4. Select patient query criteria by clicking on the **Criteria** links from the list on the left side of the screen.
5. Select the **Filter Options**:
   a. **Appointment**
   b. Search for and select **Appt Type**
   c. Select **Appointment Status**
   d. Select **Appointment Occurred**
6. Click **Save and Return**.
7. Close the window and navigate back to **Clinical Rules Editor**.
8. Click the **Refresh All** icon to review the newly created query.
9. Navigate back to TouchWorks and **Site Map** > **Patient Query**.
10. Search for and highlight the query.

IMPORTANT SAFETY INFORMATION (cont.)

WARNINGS AND PRECAUTIONS (cont.)

BLENREP Risk Evaluation and Mitigation Strategy (REMS)

BLENREP is available only through a restricted program called the BLENREP REMS because of the risk of ocular toxicity.

Further information is available at www.BLENREPREMS.com and 1-855-690-9572.

Please see additional Important Safety Information throughout and click here for full Prescribing Information including Boxed Warning for BLENREP.

BLENREP
belantamab mafodotin-blmf
for injection 70 mg

Creating Automated HCP Inbox Messages (cont.)

Steps for Creating an Inbox Message (cont.)

11. Click **New**.
12. In **Add/Edit Patient Action Set**, select **Patient Communication via Portal**.
13. Create a new action set under **Tasks**.
14. Set **User/Team to Assign Task, Task Type**, and other parameters as appropriate.
15. Use **Task Comments** to define the test to be included in the **Task** that is displayed to the recipient.
16. Navigate to **Patient Query** and select **Manage Query**.
17. Search for and highlight the query.
18. Click the **Run** icon.
19. Validate that the query has run successfully.
20. Provider tasks are automatically triggered after the query runs.



Illustrative example of new Task creation (recreated from TouchWorks®)



Illustrative example of Query success confirmation (recreated from TouchWorks)

IMPORTANT SAFETY INFORMATION (cont.)

WARNINGS AND PRECAUTIONS (cont.)

Thrombocytopenia

Thrombocytopenia of any grade occurred in 100% of patients in DREAMM-7.

Grade 2 thrombocytopenia occurred in 10% of patients, Grade 3 in 29% of patients, and Grade 4 in 45% of patients. Clinically significant bleeding (Grade ≥2) occurred in 7% of patients with concomitant low platelet levels (Grade 3 or 4).

Please see additional Important Safety Information throughout and click here for full Prescribing Information including Boxed Warning for BLENREP.

BLENREP
belantamab mafodotin-blmf
for injection 70 mg

Adding a Data Element to Document the Ocular Adverse Reaction Severity Grade

In TouchWorks®, the data element used to document the Ocular Adverse Reaction Severity Grade consists of an Orderable Item and a Resultable Item. This workflow is accomplished in 3 steps that include building the order, building the result, and attaching the result to the Orderable Item. Once created, the Orderable Item can be added to a Flowsheet.

Steps for Building the Order

1. Navigate to the **Admin Configuration Utility Tool**.
2. Navigate to **Dictionaries** and select **Orderable Item** from the dropdown menu.
3. Select the appropriate category. For example, choose **Non-Medication** > **Other Diagnostic Testing.**
4. Click the **Add** button.
5. Create an Order Name on the blank line that displays.
6. Complete each column field of the orderable item.
7. Type in the display name in the **Display Name** field.
8. Check the box for **Orderable**.
9. Click **Save**.
10. Scroll down to fill in the details on the order from the **Initial Field** to the bottom, skipping the Results field as you do not yet have a result item built.
11. Click **Save** to save the order.



Illustrative example of Orderable Item setup (recreated from TouchWorks)

IMPORTANT SAFETY INFORMATION (cont.)

WARNINGS AND PRECAUTIONS (cont.)

Thrombocytopenia (cont.)

Monitor complete blood cell counts at baseline and periodically during treatment as clinically indicated. Withhold or reduce the dose of BLENREP based on severity.

Please see additional Important Safety Information throughout and click here for full Prescribing Information including Boxed Warning for BLENREP.

BLENREP
belantamab mafodotin-blmf
for injection 70 mg

Adding a Data Element to Document the Ocular Adverse Reaction Severity Grade (cont.)

Steps for Building the Result

1. Navigate to the **Dictionary** dropdown menu and select **Resultable Item**.
2. Click **Add**.
3. Create a **Result Name** on the blank line.
4. Complete each column field of the **Resultable Item**.
5. Type in the **Display Name** in that field.
6. Select the appropriate option for the **Answer Data Type** field, for example, choose Text because it is a result that will be manually completed.
7. Scroll down to complete any additional fields as appropriate.
8. Click **Save**.



Illustrative example of Result table Item setup (recreated from TouchWorks)

IMPORTANT SAFETY INFORMATION (cont.)

WARNINGS AND PRECAUTIONS (cont.)

Embryo-fetal Toxicity

Based on its mechanism of action, BLENREP can cause fetal harm when administered to a pregnant woman because it contains a genotoxic compound (the microtubule inhibitor, monomethyl auristatin F [MMAF]) and it targets actively dividing cells.

Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with BLENREP and for 4 months after the last dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with BLENREP and for 6 months after the last dose.

Please see additional Important Safety Information throughout and click here for full Prescribing Information including Boxed Warning for BLENREP.

BLENREP
belantamab mafodotin-blmf
for injection 70 mg

Adding a Data Element to Document the Ocular Adverse Reaction Severity Grade (cont.)

Steps for Attaching the Result to the Orderable Item

1. Navigate to **Dictionaries** and select **Orderable Item** from the dropdown menu.
2. Search for the order you created and bring into context.
3. Scroll down to the **Results** section of the order.
4. Click on the **RID Selector** hyperlink.
5. The **Link Resultable Item(s) to Orderable Items** window opens.
6. Search for the resultable item that was created.
7. Highlight the correct resultable item and click the down arrow to bring it into the **Selected Resultable Items:** window.
8. Click **OK**.
9. The pop-out window closes, and you are returned to the **Orderable Item** window.
10. In the **Resultable Via:** field, select **User or Interface** from the dropdown menu.
11. Click **Save**.



Illustrative example of Linked Resultable Item to Orderable Item (recreated from TouchWorks®)

IMPORTANT SAFETY INFORMATION (cont.)

ADVERSE REACTIONS

The most common adverse reactions (≥20%) with BLENREP in combination with bortezomib and dexamethasone are reduction in BCVA, corneal exam findings, blurred vision, dry eye, photophobia, foreign body sensation in eyes, eye irritation, upper respiratory tract infection, hepatotoxicity, eye pain, diarrhea, fatigue, pneumonia, cataract and COVID-19.

Please see additional Important Safety Information throughout and click here for full Prescribing Information including Boxed Warning for BLENREP.

BLENREP
belantamab mafodotin-blmf
for injection 70 mg

Creating a Flowsheet to Document Ocular Adverse Reaction Severity Grade

Flowsheets are templates used for documentation and can be customized to capture the patient's ophthalmic exam results (conducted by either optometrists or ophthalmologists) before administration of BLENREP. Storing exam results within a Flowsheet can provide clinicians with an aggregated view of a patient's eye health and any vision changes over time. To build a Flowsheet, an order and result must be created. The order and result can then be added to a Flowsheet.

Steps for Creating an Ophthalmic Exam Flowsheet

1. Navigate to the **Flowsheet Definitions** on the toolbar menu on the left side of the page. The Flowsheet Details box displays.
2. In the **Specialty** field, select a specialty to which to assign the flowsheet.
3. Click **New**.
4. In the **Name** field, enter the name of the new flowsheet.
5. Navigate to the **Build** section of the component window.
6. Click **Add Item**.
7. The Flowsheet pop-out window displays.
8. Select the **Classification**. In this example, choose **Other Dx Testing**.
9. In the **Search For:** field, select the name of the newly created order for Ophthalmic Exam.
10. Click **GO**.
11. Click the right-facing arrow to move the **Orderable Item** to the **Selected Orderable Items:** field.
12. Click **OK**.



Illustrative example of adding data to Flowsheet template (recreated from TouchWorks®)

IMPORTANT SAFETY INFORMATION (cont.)

ADVERSE REACTIONS (cont.)

The most common Grade 3 or 4 (≥10%) laboratory abnormalities are decreased platelets, decreased lymphocytes, decreased neutrophils, increased gamma-glutamyl transferase, decreased white blood cells, and decreased hemoglobin.

Please see additional Important Safety Information throughout and click here for full Prescribing Information including Boxed Warning for BLENREP.

BLENREP
belantamab mafodotin-blmf
for injection 70 mg

Creating a Flowsheet to Document Ocular Adverse Reaction Severity Grade (cont.)

Steps for Creating an Ophthalmic Exam Flowsheet (cont.)

13. The pop-out window closes. Click **Save** on the **Flowsheets** window.
14. The Order, Result, and Flowsheet are ready to use. Navigate to the patient chart to view.

NOTE: *When an item is ordered and results have been linked to a Flowsheet, the results will automatically display in the Flowsheet in the patient's chart. In this example, you can see the Ocular Adverse Reaction Severity Grade on the Ophthalmic Exam Order Results displayed in the Flowsheet.*



Illustrative example of Flowsheet in a patient chart (recreated from TouchWorks)

INDICATION

BLENREP is indicated in combination with bortezomib and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least two prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent.

IMPORTANT SAFETY INFORMATION

WARNING: OCULAR TOXICITY

- **BLENREP causes changes in the corneal epithelium resulting in changes in vision, including severe visual impairment, and symptoms such as blurred vision and dry eyes. In the clinical study, corneal ulcers, including cases with infection, also occurred.**
- **Conduct ophthalmic exams at baseline, before each dose, promptly for new or worsening symptoms, and as clinically indicated. In the clinical study, 83% of patients required a dosage modification due to ocular toxicity. Withhold BLENREP until improvement and resume or permanently discontinue, based on severity.**
- **Because of the risk of ocular toxicity, BLENREP is available only through a restricted program called the BLENREP Risk Evaluation and Mitigation Strategy (REMS).**

Please see additional Important Safety Information throughout and click here for full Prescribing Information including Boxed Warning for BLENREP.

BLENREP
belantamab mafodotin-blmf
for injection 70 mg

Creating an Auto Text to View or Document Ocular Adverse Reaction Severity Grade

An Auto Text phrase, or a Macro, can be created to insert documented grading based on ophthalmic exam results into visit notes. Auto Text are shortcuts that insert predefined text into patient notes, discharge instructions, or other documentation using an abbreviated phrase. By typing a period (.) followed by the phrase, the predefined text associated with that phrase is automatically inserted.

Steps for Creating a New Auto Text

1. Click on the **Macro** icon.
2. The **My Macros** page displays.
3. Click the **Create** button.
4. The **Create New Macro** window displays.
5. In the **Shortcut:** field type in the shortcut you will use for the new macro.
6. In the **Description:** field type in a description of the new macro.
7. Type the text to be displayed when the macro is invoked (see table on the next page).
8. Click **Save** to save the new macro.



Illustrative example of New Macro setup (recreated from TouchWorks)

IMPORTANT SAFETY INFORMATION (cont.)

WARNINGS AND PRECAUTIONS

Ocular Toxicity

BLENREP causes ocular toxicity, defined as changes in the corneal epithelium and changes in BCVA based on ophthalmic exam (including slit lamp exam), or other ocular adverse reactions as defined by the CTCAE.

In DREAMM-7, ocular toxicity occurred in 92% of patients, including Grade 3 or 4 in 77% of patients. The most common ocular toxicities (>25%) were reduction in BCVA (89%) and corneal exam findings (86%) based on ophthalmic exam findings, blurred vision (66%), dry eye (51%), photophobia (47%), foreign body sensation in eyes (44%), eye irritation (43%), and eye pain (33%).

Please see additional Important Safety Information throughout and click here for full Prescribing Information including Boxed Warning for BLENREP.

BLENREP
belantamab mafodotin-blmf
for injection 70 mg

Creating an Auto Text to View or Document Ophthalmic Exam Results (cont.)

Recommended Dosage Modifications for Ocular Toxicity based on Ophthalmic Exam Findings[1]	
Grade 1	Continue treatment at current dosage.
Grade 2	Withhold BLENREP until improvement in both corneal exam findings and change in BCVA to Grade 1 or less. Resume treatment at Reduced Dosage Level 1 as per Table 1. If recurrent Grade 2 or 3 ocular toxicity is experienced, resume treatment at Reduced Dosage Level 2.
Grade 3	Withhold BLENREP until improvement in both corneal exam findings and change in BCVA to Grade 1 or less. Resume treatment at Reduced Dosage Level 1 as per Table 1. If recurrent Grade 2 or 3 ocular toxicity is experienced, resume treatment at Reduced Dosage Level 2.
Grade 4	Consider permanent discontinuation of BLENREP. If continuing treatment, withhold BLENREP until improvement in both corneal exam findings and change in BCVA to Grade 1 or less. For patients previously on 2.5 mg/kg every 3 weeks, resume treatment at Reduced Dosage Level 1 as per Table 1. For patients previously on 1.9 mg/kg every 3 weeks, resume treatment at Reduced Dosage Level 2. If recurrent Grade 4 ocular toxicity is experienced, permanently discontinue BLENREP.

For more information on grading definitions and dose modifications for ocular toxicity and non-ocular adverse reactions, please see the full Prescribing Information.

IMPORTANT SAFETY INFORMATION (cont.)

WARNINGS AND PRECAUTIONS (cont.)

Ocular Toxicity (cont.)

Ocular toxicity based on ophthalmic exam findings was reported as Grade 2 in 9% of patients, Grade 3 in 56% of patients, and Grade 4 in 21% of patients. The median time to onset of the first Grade 2 to 4 ophthalmic exam findings was 43 days (range: 15 to 611 days). The median duration of all Grade 2 to 4 ophthalmic exam findings was 85 days (range: 5 to 813 days). Patients experienced a median of 3 episodes (range: 1 to 11 episodes) of ocular toxicity based on ophthalmic exam findings. Of the patients with Grade 2 to 4 ophthalmic exam findings, 42% had improvement of the last event to Grade 1 or better; 22% had resolution of the last event based on return to baseline or normal ophthalmic exam findings.

Reference: 1. BLENREP. Prescribing Information. GSK; 2025.

Please see additional Important Safety Information throughout and click here for full Prescribing Information including Boxed Warning for BLENREP.

Trademarks are property of their respective owners.
©2025 GSK or licensor.
PMUS-BLMBRGD250004 October 2025
Produced in USA.

BLENREP belantamab mafodotin-blmf for injection 70 mg